drugset / Trial / NCT01820728

A Phase III Clinical Study to Compare the Efficacy and Safety of DA-3801 and That of Gonal-F®

NCT01820728

Phase 3 Completed 93 enrolled Dong-A ST Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

open label, active-controlled, randomized, parallel group, comparative study.

Timeline

Start
2007-01
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-3801 Protein / enzyme biologic 75 iu
Comparator Gonal-f Protein / enzyme biologic 75 iu